☆ 4.6 Article

Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis

PHARMACEUTICALS (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Management of immune-related cutaneous adverse events with dupilumab

Alyce Mei-Shiuan Kuo et al.

Summary: Immune checkpoint inhibitors (ICI) can effectively target cancer cells, but they may also cause immune-related cutaneous adverse events (ircAEs) in a significant number of patients. This study examined the use of dupilumab for treating ICI-associated ircAEs and found that 87% of patients responded to the treatment, with 44.1% achieving complete resolution of the adverse events.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Add to Collection

Article Dermatology

European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement

Z. Apalla et al.

Summary: The introduction of ICIs revolutionized oncologic therapy but also brought the risk of irAEs, with dermatologic irAEs being common. The EADV task force provided treatment recommendations for skin toxicities, focusing on balancing symptom relief with ongoing oncologic treatment.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Review Oncology

Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways

Lukas Kraehenbuehl et al.

Summary: The discovery and clinical implementation of immune-checkpoint inhibitors like CTLA4, PD-1, and PD-L1 have significantly improved outcomes for patients with advanced-stage cancers. However, a majority of patients do not respond to these agents, emphasizing the need for further research into alternative immunomodulatory pathways and targeting tumor metabolism to enhance treatment efficacy.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Hussein A. Tawbi et al.

Summary: LAG-3 and PD-1 are two distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab and nivolumab has been shown to be safe and effective in previously treated melanoma patients, and this study aimed to evaluate its safety and activity in previously untreated melanoma patients. The results demonstrated that the combination therapy provided a greater benefit in terms of progression-free survival compared to nivolumab alone, without any new safety signals.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Dermatology

Oncodermatology: Advancing the Science and Care of Cancer Patients and Survivors

Alexander S. Bang et al.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2022)

Add to Collection

Article Oncology

Contribution of the Skin-Gut Axis to Immune-Related Adverse Events with Multi-System Involvement

Alyce M. Kuo et al.

Summary: An increasing number of cancer patients are treated with immunotherapy, but a proportion of them experience adverse events in the skin and gastrointestinal tract. This study suggests that in patients who develop both skin and gastrointestinal adverse events, the skin events are likely to occur first. Further research is needed to validate these findings and assess the overall incidence of co-incident adverse events.

CANCERS (2022)

Add to Collection

Article Oncology

Clinical Presentation and Prognostic Features in Patients with Immunotherapy-Induced Vitiligo-like Depigmentation: A Monocentric Prospective Observational Study

Nicola Hermann et al.

Summary: This study investigated the clinical and biological features of VLD in melanoma patients receiving immunotherapy, revealing a unique immune signature in VLD patients and distinct proteomic profiles in VLD responders. These findings suggest that VLD may have potential implications for treatment response and prognosis in melanoma patients undergoing CPI therapy.

CANCERS (2022)

Add to Collection

Review Allergy

Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy

Elena Goleva et al.

Summary: This review provides insights into the mechanism of action of immune checkpoint inhibitors in cancer therapy, emphasizing the need for further research to develop new strategies to reduce negative side effects while preserving the benefits of immunotherapy.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)

Add to Collection

Review Allergy

Immune-related cutaneous adverse events due to checkpoint inhibitors

Evelyn Wang et al.

Summary: This article provides an overview of the most common cutaneous adverse events caused by immune checkpoint inhibitors, including their grading and treatment, aiming to help healthcare professionals identify and manage these issues effectively.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)

Add to Collection

Article Dermatology

Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity

L. L. Thompson et al.

Summary: Dermatologist-evaluated cirAEs were more likely to receive treatment than non-referred cirAEs, and patients receiving any cirAE treatment showed improved survival outcomes.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Article Oncology

Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy

Mario E. Lacouture et al.

Summary: Topical therapy with BRAF inhibitor has shown to be safe and effective in improving skin toxicities induced by EGFR inhibitors, potentially avoiding dose reductions.

CANCER DISCOVERY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Signal pathways of melanoma and targeted therapy

Weinan Guo et al.

Summary: Melanoma, a lethal skin cancer, has limited therapeutic options. Innovations in targeting mutated driver genes and immune checkpoints have improved patient prognosis, but resistance and low response rates remain challenges in melanoma treatment.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Article Dermatology

Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study

D. M. Barrios et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

Add to Collection

Article Dermatology

Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center

Zizi Yu et al.

JAMA DERMATOLOGY (2020)

Add to Collection

Review Immunology

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions

Massimo Ralli et al.

JOURNAL OF IMMUNOLOGY RESEARCH (2020)

Add to Collection

Article Oncology

Treatment Outcomes of Immune-Related Cutaneous Adverse Events

Gregory S. Phillips et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Dermatology

The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma

N. P. Graf et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2019)

Add to Collection

Article Oncology

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial

Reinhard Dummer et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Pharmacology & Pharmacy

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis

Peng-Fei Wang et al.

FRONTIERS IN PHARMACOLOGY (2017)

Add to Collection

Article Oncology

Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy

Simone M. Goldinger et al.

CLINICAL CANCER RESEARCH (2016)

Add to Collection

Article Oncology

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

V. R. Belum et al.

EUROPEAN JOURNAL OF CANCER (2016)

Add to Collection

Review Oncology

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

J. Naidoo et al.

ANNALS OF ONCOLOGY (2015)

Add to Collection

Article Oncology

Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

Michele Maio et al.

JOURNAL OF CLINICAL ONCOLOGY (2015)

Add to Collection

Article Dermatology

Cutaneous adverse effects of targeted therapies Part II: Inhibitors of intracellular molecular signaling pathways

James B. Macdonald et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Dermatology

Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib

Rachael Anforth et al.

AUSTRALASIAN JOURNAL OF DERMATOLOGY (2014)

Add to Collection

Article Medicine, General & Internal

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

James Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Review Oncology

Cutaneous toxicities of RAF inhibitors

Rachael Anforth et al.

LANCET ONCOLOGY (2013)

Add to Collection

Article Medicine, General & Internal

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Medicine, General & Internal

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Keith T. Flaherty et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Oncology

Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

Georgina V. Long et al.

JOURNAL OF CLINICAL ONCOLOGY (2011)

Add to Collection

Article Medicine, General & Internal

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Add to Collection

Review Pharmacology & Pharmacy

BRAF as therapeutic target in melanoma

Claudia Wellbrock et al.

BIOCHEMICAL PHARMACOLOGY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.